Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADACAL Study
2011-003966-34Phase 3Completed
- Sponsor
- GETECCU
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab in Crohn's disease (2 arms), sponsored by GETECCU. Primary endpoint: Rate of therapeutic failure up to week 48. Started Oct 2011; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-003966-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003966-34.